Skip to content
Catalyst

acrylamideWhat was measured

Measured, with no finding

445 endpoints

Show what was measuredHide what was measured
  • Correlation of energy-adjusted acrylamide intake with alcohol intake

    decreases

    The highest correlations between energy-adjusted acrylamide intake and dietary factors were between acrylamide intake and coffee (r=0.63), fried potatoes (r=0.50), fiber (r=0.25), rye bread (r=0.23), and alcohol intake (r=−0.22)

    PMID 20859673 · one of two readings recorded this

  • Correlation of energy-adjusted acrylamide intake with coffee intake

    increases

    The highest correlations between energy-adjusted acrylamide intake and dietary factors were between acrylamide intake and coffee (r=0.63), fried potatoes (r=0.50), fiber (r=0.25), rye bread (r=0.23), and alcohol intake (r=−0.22)

    PMID 20859673 · one of two readings recorded this

  • Correlation of energy-adjusted acrylamide intake with fiber intake

    increases

    The highest correlations between energy-adjusted acrylamide intake and dietary factors were between acrylamide intake and coffee (r=0.63), fried potatoes (r=0.50), fiber (r=0.25), rye bread (r=0.23), and alcohol intake (r=−0.22)

    PMID 20859673 · one of two readings recorded this

  • Correlation of energy-adjusted acrylamide intake with fried potatoes intake

    increases

    The highest correlations between energy-adjusted acrylamide intake and dietary factors were between acrylamide intake and coffee (r=0.63), fried potatoes (r=0.50), fiber (r=0.25), rye bread (r=0.23), and alcohol intake (r=−0.22)

    PMID 20859673 · one of two readings recorded this

  • Correlation of energy-adjusted acrylamide intake with rye bread intake

    increases

    The highest correlations between energy-adjusted acrylamide intake and dietary factors were between acrylamide intake and coffee (r=0.63), fried potatoes (r=0.50), fiber (r=0.25), rye bread (r=0.23), and alcohol intake (r=−0.22)

    PMID 20859673 · one of two readings recorded this

  • Dietary acrylamide intake from coffee

    coffee 15.2 μg/day (40.4 %)

    PMID 20859673 · one of two readings recorded this

  • Dietary acrylamide intake from fried potatoes

    fried potatoes 5.47 μg/day (14.6 %)

    PMID 20859673 · one of two readings recorded this

  • Dietary acrylamide intake from rye bread

    and rye bread 5.26 μg/day (14.0 %)

    PMID 20859673 · one of two readings recorded this

  • incidence of prostate, urothelial, colorectal, stomach, pancreatic, renal cell cancer and lymphoma, proportional hazards RR highest vs lowest quintile

    no effect, no association observed

    Not recorded as a finding: the only sentence is a lumped statement about 'other cancers' that names no single cancer, so no per-node span can be anchored; urothelial, renal and lymphoma have no node

    No association was observed between acrylaimide intake and other cancers (Table 2).

    PMID 20859673 · one of two readings recorded this

  • Incident colorectal cancer cases during follow-up

    n = 316

    During the 10.2 years of follow-up 1703 lung cancers, 799 prostate cancers, 365 urothelial cancers, 316 colorectal cancers,224 stomach cancers, 192 pancreatic cancers, 184 renal cell cancers, and 175 lymphomas were diagnosed

    PMID 20859673 · one of two readings recorded this

  • Incident lymphoma cases during follow-up

    n = 175

    During the 10.2 years of follow-up 1703 lung cancers, 799 prostate cancers, 365 urothelial cancers, 316 colorectal cancers,224 stomach cancers, 192 pancreatic cancers, 184 renal cell cancers, and 175 lymphomas were diagnosed

    PMID 20859673 · one of two readings recorded this

  • Incident pancreatic cancer cases during follow-up

    n = 192

    During the 10.2 years of follow-up 1703 lung cancers, 799 prostate cancers, 365 urothelial cancers, 316 colorectal cancers,224 stomach cancers, 192 pancreatic cancers, 184 renal cell cancers, and 175 lymphomas were diagnosed

    PMID 20859673 · one of two readings recorded this

  • Incident prostate cancer cases during follow-up

    n = 799

    During the 10.2 years of follow-up 1703 lung cancers, 799 prostate cancers, 365 urothelial cancers, 316 colorectal cancers,224 stomach cancers, 192 pancreatic cancers, 184 renal cell cancers, and 175 lymphomas were diagnosed

    PMID 20859673 · one of two readings recorded this

  • Incident renal cell cancer cases during follow-up

    n = 184

    During the 10.2 years of follow-up 1703 lung cancers, 799 prostate cancers, 365 urothelial cancers, 316 colorectal cancers,224 stomach cancers, 192 pancreatic cancers, 184 renal cell cancers, and 175 lymphomas were diagnosed

    PMID 20859673 · one of two readings recorded this

  • Incident stomach cancer cases during follow-up

    n = 224

    During the 10.2 years of follow-up 1703 lung cancers, 799 prostate cancers, 365 urothelial cancers, 316 colorectal cancers,224 stomach cancers, 192 pancreatic cancers, 184 renal cell cancers, and 175 lymphomas were diagnosed

    PMID 20859673 · one of two readings recorded this

  • Incident urothelial cancer cases during follow-up

    n = 365

    During the 10.2 years of follow-up 1703 lung cancers, 799 prostate cancers, 365 urothelial cancers, 316 colorectal cancers,224 stomach cancers, 192 pancreatic cancers, 184 renal cell cancers, and 175 lymphomas were diagnosed

    PMID 20859673 · one of two readings recorded this

  • Lung cancer risk, age- and supplementation-adjusted

    increases, p = 0.02, n = 1703

    relative risk (RR) 1.26 (95% confidence interval (CI) 1.09–1.47), p for trend=0.02

    PMID 20859673 · one of two readings recorded this

  • Lung cancer risk, cases in first 2 years excluded

    no effect

    When analyses were repeated with exclusion of the cases that occurred during the first 2 years the results were unchanged

    PMID 20859673 · one of two readings recorded this

  • Lung cancer risk, multivariate-adjusted

    increases, p = 0.02, n = 1703

    RR 1.27 (95% CI 1.08–1.49), p for trend=0.02, respectively in the highest vs. lowest quintile

    PMID 20859673 · one of two readings recorded this

  • Lung cancer risk, multivariate model further adjusted for coffee

    no effect, p = 0.55

    adjustment for coffee RR 1.12 (95% CI 0.92–1.36), p for trend=0.55

    PMID 20859673 · one of two readings recorded this

  • Lung cancer risk, multivariate model further adjusted for fried potatoes

    increases, p = 0.05

    for fried potatoes RR 1.26 (95% CI 1.05–1.51), p for trend =0.05

    PMID 20859673 · one of two readings recorded this

  • Lung cancer risk, multivariate model further adjusted for rye bread

    increases, p = 0.02

    for rye bread RR 1.25 (95% CI 1.07–1.47), p for trend=0.02

    PMID 20859673 · one of two readings recorded this

  • Lung cancer risk

    unclear, p = 0.03

    RR of highest quintile vs. lowest 1.17 (95% CI 0.99–1.37), p for trend 0.03

    PMID 20859673 · one of two readings recorded this

  • Lung cancer risk

    no effect

    Consumption of fried potatoes or rye bread were not associated with the risk of lung cancer

    PMID 20859673 · one of two readings recorded this

  • other cancers pooled (prostate, urothelial, colorectal, stomach, pancreatic, renal cell, lymphoma), incidence by quintile of acrylamide intake

    no effect, No association observed

    Not recorded as a finding: The results sentence reports no association for 'other cancers' collectively with no per-site estimate; no per-site quoted sentence to anchor

    No association was observed between acrylaimide intake and other cancers (Table 2).

    PMID 20859673 · one of two readings recorded this

  • Other cancers (prostate, urothelial, colorectal, stomach, pancreatic, renal cell, lymphoma)

    no effect

    No association was observed between acrylaimide intake and other cancers

    PMID 20859673 · one of two readings recorded this

  • Validation correlation, first questionnaire vs food records, dietary acrylamide

    n = 190

    The Spearman correlations between the first and second questionnaires and the food records were 0.73 and 0.43, respectively for dietary acrylamide

    PMID 20859673 · one of two readings recorded this

  • Validation correlation, second questionnaire vs food records, dietary acrylamide

    The Spearman correlations between the first and second questionnaires and the food records were 0.73 and 0.43, respectively for dietary acrylamide

    PMID 20859673 · one of two readings recorded this

  • AAVal and GAVal change from 1. BS to 2. BS

    decreases, p = 0.05

    Signals for AAVal as well as GAVal (p < 0.05) of group A decreased from initial blood sampling (1. BS, begin of study) to the subsequent sampling time point (2. BS, day 7)

    PMID 28534225 · one of two readings recorded this

  • AAVal and GAVal decline over 13-day washout

    decreases, p = 0.05

    the AAVal and GAVal levels declined at following blood sampling time points (p < 0.05)

    PMID 28534225 · one of two readings recorded this

  • AAVal and GAVal response to high AA intake at 3. BS

    increases, p = 0.05

    Both values responded to high AA intake on day 10 within 3 days (3. BS, day 13; p < 0.05)

    PMID 28534225 · one of two readings recorded this

  • Caloric intake on high AA day 10

    The caloric intake on day 10 (high AA, group A) was 2897 kcal (+20%)

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary 13C3D3-AAMA after 13C3D3-AA

    13C3D3-AAMA (nmol) | 303 ± 39 | 377 ± 52 | 403 ± 58 | 412 ± 60 | 414 ± 62

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary 13C3D3-AAMA after 13C3D3-AA

    13C3D3-AAMA (nmol) | 303 ± 39 | 377 ± 52 | 403 ± 58 | 412 ± 60 | 414 ± 62

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary 13C3D3-AAMA after 13C3D3-AA

    13C3D3-AAMA (nmol) | 303 ± 39 | 377 ± 52 | 403 ± 58 | 412 ± 60 | 414 ± 62

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary 13C3D3-AAMA after 13C3D3-AA

    13C3D3-AAMA (nmol) | 303 ± 39 | 377 ± 52 | 403 ± 58 | 412 ± 60 | 414 ± 62

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary 13C3D3-AAMA after 13C3D3-AA

    13C3D3-AAMA (nmol) | 303 ± 39 | 377 ± 52 | 403 ± 58 | 412 ± 60 | 414 ± 62

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary AAMA after high AA intake

    AAMA (nmol) | 91 ± 54 | 3654 ± 824 | 5950 ± 780 | 6811 ± 865 | 7089 ± 875

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary AAMA after high AA intake

    AAMA (nmol) | 91 ± 54 | 3654 ± 824 | 5950 ± 780 | 6811 ± 865 | 7089 ± 875

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary AAMA after high AA intake

    AAMA (nmol) | 91 ± 54 | 3654 ± 824 | 5950 ± 780 | 6811 ± 865 | 7089 ± 875

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary AAMA after high AA intake

    AAMA (nmol) | 91 ± 54 | 3654 ± 824 | 5950 ± 780 | 6811 ± 865 | 7089 ± 875

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary AAMA, washout day 9 (24 h)

    AAMA (nmol) | 91 ± 54 | 3654 ± 824 | 5950 ± 780 | 6811 ± 865 | 7089 ± 875

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary GAMA after high AA intake

    GAMA (nmol) | 25 ± 12 | 270 ± 58 | 628 ± 115 | 774 ± 133 | 854 ± 149

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary GAMA after high AA intake

    GAMA (nmol) | 25 ± 12 | 270 ± 58 | 628 ± 115 | 774 ± 133 | 854 ± 149

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary GAMA after high AA intake

    GAMA (nmol) | 25 ± 12 | 270 ± 58 | 628 ± 115 | 774 ± 133 | 854 ± 149

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary GAMA after high AA intake

    GAMA (nmol) | 25 ± 12 | 270 ± 58 | 628 ± 115 | 774 ± 133 | 854 ± 149

    PMID 28534225 · one of two readings recorded this

  • Cumulative urinary GAMA, washout day 9 (24 h)

    GAMA (nmol) | 25 ± 12 | 270 ± 58 | 628 ± 115 | 774 ± 133 | 854 ± 149

    PMID 28534225 · one of two readings recorded this

  • Estimated daily caloric intake during washout

    The estimated daily caloric intake during washout was 2408 ± 83 kcal

    PMID 28534225 · one of two readings recorded this

  • Fraction of 13C3D3-AA excreted as 13C3D3-AAMA

    After 24 h 30% of 13C3D3-AA intake was excreted as 13C3D3-AAMA

    PMID 28534225 · one of two readings recorded this

  • Fraction of 13C3D3-AA excreted as 13C3D3-AAMA

    after 72 h 40%

    PMID 28534225 · one of two readings recorded this

  • Fraction of 13C3D3-AA excreted as 13C3D3-AAMA

    after 96 h in total 41% of the ingested 13C3D3-AA were excreted as 13C3D3-AAMA

    PMID 28534225 · one of two readings recorded this

  • Fraction of ingested AA excreted as AAMA

    After 24 h about 23% (15–29%) of ingested AA were excreted

    PMID 28534225 · one of two readings recorded this

  • Fraction of ingested AA excreted as AAMA

    after 96 h about 44% (38–51%)

    PMID 28534225 · one of two readings recorded this

  • Fraction of ingested AA excreted as GAMA

    Corresponding values for GAMA were about 2% (24 h) and about 5% (96 h)

    PMID 28534225 · one of two readings recorded this

  • Fraction of ingested AA excreted as GAMA

    Corresponding values for GAMA were about 2% (24 h) and about 5% (96 h)

    PMID 28534225 · one of two readings recorded this

  • Hemoglobin adduct AAVal, 1. BS

    1. BS | 24.5 ± 19.7 | 46.4 ± 44.1 | 17.2 ± 16.0 | 27.5 ± 25.8

    PMID 28534225 · one of two readings recorded this

  • Hemoglobin adduct AAVal, 2. BS (day 7)

    2. BS | 22.3 ± 17.6 | 38.4 ± 34.9 | 15.9 ± 14.5 | 23.3 ± 21.5

    PMID 28534225 · one of two readings recorded this

  • Hemoglobin adduct AAVal, 3. BS (day 13)

    3. BS | 26.0 ± 16.1 | 34.0 ± 32.6 | 18.7 ± 13.5 | 20.9 ± 20.7

    PMID 28534225 · one of two readings recorded this

  • Hemoglobin adduct GAVal, 1. BS

    1. BS | 24.5 ± 19.7 | 46.4 ± 44.1 | 17.2 ± 16.0 | 27.5 ± 25.8

    PMID 28534225 · one of two readings recorded this

  • Hemoglobin adduct GAVal, 2. BS (day 7)

    2. BS | 22.3 ± 17.6 | 38.4 ± 34.9 | 15.9 ± 14.5 | 23.3 ± 21.5

    PMID 28534225 · one of two readings recorded this

  • Hemoglobin adduct GAVal, 3. BS (day 13)

    3. BS | 26.0 ± 16.1 | 34.0 ± 32.6 | 18.7 ± 13.5 | 20.9 ± 20.7

    PMID 28534225 · one of two readings recorded this

  • N-terminal valine hemoglobin adducts AAVal and GAVal, UHPLC-ESI-MS/MS

    increases, adduct levels responded to high AA intake within 3 days, n = 6

    Not recorded as a finding: No node in the outcome list for hemoglobin adducts of acrylamide

    Both values responded to high AA intake on day 10 within 3 days (3. BS, day 13; p < 0.05).

    PMID 28534225 · one of two readings recorded this

  • urinary AAMA and GAMA mercapturic acid excretion after dietary acrylamide, creatinine-normalised, UHPLC-ESI-MS/MS

    increases, AAMA excretion steeply increased after high-AA meal on day 10, n = 6

    Not recorded as a finding: No node in the outcome list for urinary acrylamide mercapturic acid excretion

    As seen from Fig. 4, after high AA intake at day 10 (14.1–15.9 µg/kg bw/d), a steep increase of AAMA and GAMA excretion was observed.

    PMID 28534225 · one of two readings recorded this

  • Urinary AAMA excretion after coffee, day 6

    increases

    led to slightly enhanced urinary mean AAMA excretion (0.15 ± 0.06 µmol/d), as compared to 0.12 ± 0.05 µmol/d on the foregoing day 5

    PMID 28534225 · one of two readings recorded this

  • Urinary AAMA excretion, day 1

    excreting urinary AAMA amounts of 0.52 ± 0.39 µmol (0.29 ± 0.23 µmol/g ucr) on day 1

    PMID 28534225 · one of two readings recorded this

  • Urinary AAMA excretion, day 5

    decreases

    continuously decreasing to 0.19 ± 0.14 µmol (0.08 ± 0.06 µmol/g ucr) on day 5

    PMID 28534225 · one of two readings recorded this

  • Urinary AAMA excretion, day 9

    decreases

    Until day 9 the mean values of group A were decreasing to 0.09 ± 0.05 µmol/d (range 0.04–0.19 µmol/d)

    PMID 28534225 · one of two readings recorded this

  • Urinary AAMA excretion, end of 13-day washout

    decreases

    the respective day 5 value (washout) of group B was 0.19 ± 0.14 µmol/d, decreasing towards the end of the study to 0.14 ± 0.10 µmol/d

    PMID 28534225 · one of two readings recorded this

  • Urinary AAMA excretion, washout days 1 to 5

    decreases

    During the first washout phase (days 1–5) the AAMA excretion of group A decreased from 0.28 ± 0.14 µmol/d (0.16 ± 0.09 µmol/g ucr) to 0.12 ± 0.05 µmol/d (0.06 ± 0.04 µmol/g ucr)

    PMID 28534225 · one of two readings recorded this

  • Urinary GAMA excretion, day 1 to day 5

    decreases

    The GAMA excretion (shown in Fig. 4 in relation to creatinine excretion) decreased in group A from 0.06 ± 0.01 µmol (0.03 ± 0.02 µmol/g ucr) on day 1 to 0.03 ± 0.01 µmol (0.02 ± 0.01 µmol/g ucr) on day 5

    PMID 28534225 · one of two readings recorded this

  • Urinary GAMA excretion, day 1 to day 5

    decreases

    Values for GAMA in group B were 0.08 ± 0.06 µmol (0.04 ± 0.03 µmol/g ucr) on day 1 and 0.05 ± 0.03 µmol (0.02 ± 0.01 µmol/g ucr) on day 5

    PMID 28534225 · one of two readings recorded this

  • urinary mercapturic acid (AAMA, GAMA) excretion after high dietary acrylamide intake, UHPLC-ESI-MS/MS

    increases, steep increase of AAMA and GAMA excretion after 14.1-15.9 ug/kg bw

    Not recorded as a finding: no outcome node for urinary acrylamide mercapturic acid excretion; also uncontrolled within-group change

    As seen from Fig. 4, after high AA intake at day 10 (14.1–15.9 µg/kg bw/d), a steep increase of AAMA and GAMA excretion was observed.

    PMID 28534225 · one of two readings recorded this

  • childhood overweight/obesity risk at age 3, 5 and 8, pooled OR

    increases, OR 1.14 at age 3; 1.13 at age 5; 1.09 at age 8

    Not recorded as a finding: no outcome node for childhood overweight/obesity incidence

    In addition, pooled ORs suggested that children had a high risk of developing overweight/obesity in the future in maternal high AA exposure group (OR 1·14, 95 % CI 1·08, 1·21, P < 0·001 at age 3; OR 1·13, 95 % CI 1·07, 1·19, P < 0·001 at age 5; OR 1·09, 95 % CI 1·02, 1·16, P = 0·020 at age 8).

    PMID 32349855 · one of two readings recorded this

  • Offspring birth weight

    decreases, p = 0.005

    Offspring's birth weight was significantly lower in high AA exposure group than in low AA exposure group (SMD -0·05, 95 % CI -0·09, -0·02, P = 0·005)

    PMID 32349855 · one of two readings recorded this

  • Offspring overweight/obesity

    increases, p = 0.001

    OR 1·14, 95 % CI 1·08, 1·21, P < 0·001 at age 3

    PMID 32349855 · one of two readings recorded this

  • Offspring overweight/obesity

    increases, p = 0.001

    OR 1·13, 95 % CI 1·07, 1·19, P < 0·001 at age 5

    PMID 32349855 · one of two readings recorded this

  • Offspring overweight/obesity

    increases, p = 0.02

    OR 1·09, 95 % CI 1·02, 1·16, P = 0·020 at age 8

    PMID 32349855 · one of two readings recorded this

  • small for gestational age (binary), pooled OR

    increases, OR 1.14, 95% CI 1.06, 1.23

    Not recorded as a finding: no outcome node for small-for-gestational-age incidence

    There was also an association between maternal AA exposure and small for gestational age (OR 1·14, 95 % CI 1·06, 1·23, P < 0·001).

    PMID 32349855 · one of two readings recorded this

  • small for gestational age, pooled OR; and overweight/obesity at ages 3, 5 and 8, pooled ORs

    increases, SGA OR 1·14, 95 % CI 1·06, 1·23

    Not recorded as a finding: No node in the outcome list for small-for-gestational-age or childhood overweight/obesity

    There was also an association between maternal AA exposure and small for gestational age (OR 1·14, 95 % CI 1·06, 1·23, P < 0·001).

    PMID 32349855 · one of two readings recorded this

  • Small for gestational age

    increases, p = 0.001

    There was also an association between maternal AA exposure and small for gestational age (OR 1·14, 95 % CI 1·06, 1·23, P < 0·001)

    PMID 32349855 · one of two readings recorded this

  • contribution to total acrylamide intake

    biscuits and cookies (men, 8.0%; women, 12.8%)

    PMID 32806637 · one of two readings recorded this

  • contribution to total acrylamide intake

    biscuits and cookies (men, 8.0%; women, 12.8%)

    PMID 32806637 · one of two readings recorded this

  • contribution to total acrylamide intake

    coffee (men, 32.0%; women, 23.6%)

    PMID 32806637 · one of two readings recorded this

  • contribution to total acrylamide intake

    coffee (men, 32.0%; women, 23.6%)

    PMID 32806637 · one of two readings recorded this

  • contribution to total acrylamide intake

    green tea (men, 20.2%; women, 22.8%)

    PMID 32806637 · one of two readings recorded this

  • contribution to total acrylamide intake

    green tea (men, 20.2%; women, 22.8%)

    PMID 32806637 · one of two readings recorded this

  • contribution to total acrylamide intake

    potatoes and starches (men, 10.4%; women, 12.8%)

    PMID 32806637 · one of two readings recorded this

  • contribution to total acrylamide intake

    potatoes and starches (men, 10.4%; women, 12.8%)

    PMID 32806637 · one of two readings recorded this

  • contribution to total acrylamide intake

    vegetables (men, 9.9%; women, 11.5%)

    PMID 32806637 · one of two readings recorded this

  • contribution to total acrylamide intake

    vegetables (men, 9.9%; women, 11.5%)

    PMID 32806637 · one of two readings recorded this

  • incident lung cancer (ICD-O-3 C34) by cancer registry and hospital notification, Cox hazard ratio for quartiles and per 10 ug/day increment of energy-adjusted dietary acrylamide intake (FFQ), analysed separately in men and in women

    no effect, p = 0.12

    Not recorded as a finding: every result is a subgroup, with no whole-population estimate

    No association was observed between daily acrylamide intake and lung cancer overall (p for trend = 0.12).

    PMID 32806637 · one of two readings recorded this

  • incident lung cancer (ICD-O-3 C34, registry-ascertained) by quartile of energy-adjusted dietary acrylamide intake, multivariable Cox HR, analysed separately in men and in women

    no effect, p = 0.12

    Not recorded as a finding: every result is a subgroup, with no whole-population estimate

    No association was observed between daily acrylamide intake and lung cancer overall (p for trend = 0.12).

    PMID 32806637 · one of two readings recorded this

  • lung adenocarcinoma incident cases

    there were 379 adenocarcinomas

    PMID 32806637 · one of two readings recorded this

  • lung adenocarcinoma incident cases

    there were 358 adenocarcinomas

    PMID 32806637 · one of two readings recorded this

  • lung cancer incident cases

    At the end of the follow-up period, 1187 lung cancer cases were newly identified in men

    PMID 32806637 · one of two readings recorded this

  • lung cancer incident cases

    A total of 485 cases were newly identified in women

    PMID 32806637 · one of two readings recorded this

  • lung cancer risk, p for trend across quartiles

    no effect, p = 0.12

    No association was observed between daily acrylamide intake and lung cancer overall (p for trend = 0.12)

    PMID 32806637 · one of two readings recorded this

  • lung cancer risk, p for trend across quartiles

    no effect, p = 0.86

    Acrylamide intake was not associated with lung cancer risk by increasing acrylamide intake both in the overall analysis (p for trend = 0.86) and sensitivity analysis (p for trend = 0.86)

    PMID 32806637 · one of two readings recorded this

  • lung cancer risk, p for trend across quartiles

    no effect, p = 0.86

    Acrylamide intake was not associated with lung cancer risk by increasing acrylamide intake both in the overall analysis (p for trend = 0.86) and sensitivity analysis (p for trend = 0.86)

    PMID 32806637 · one of two readings recorded this

  • lung cancer risk per 10-µg/day increment

    no effect

    The HR of lung cancer for 10-µg/day increment of acrylamide intake was 1.01 (95% CI, 0.99–1.02)

    PMID 32806637 · one of two readings recorded this

  • lung cancer risk per continuous acrylamide intake

    no effect

    When acrylamide intake was considered a continuous variable, the HR was 0.98 (95% CI, 0.95–1.01)

    PMID 32806637 · one of two readings recorded this

  • lung cancer risk per continuous acrylamide intake

    no effect

    no evidence of a decreased risk of lung cancer (HR, 0.98; 95% CI, 0.93–1.02) was observed when acrylamide intake was treated as a continuous variable

    PMID 32806637 · one of two readings recorded this

  • lung squamous cell carcinoma incident cases

    323 squamous cell carcinomas

    PMID 32806637 · one of two readings recorded this

  • mean daily acrylamide intake

    The mean (standard deviation) daily acrylamide intakes were 6.8 (3.9) µg/day in men and 7.0 (3.7) µg/day in women

    PMID 32806637 · one of two readings recorded this

  • mean daily acrylamide intake

    The mean (standard deviation) daily acrylamide intakes were 6.8 (3.9) µg/day in men and 7.0 (3.7) µg/day in women

    PMID 32806637 · one of two readings recorded this

  • other and unclassified lung cancer incident cases

    345 others and unclassified cases

    PMID 32806637 · one of two readings recorded this

  • other and unclassified lung cancer incident cases

    127 others and unclassified cases

    PMID 32806637 · one of two readings recorded this

  • small-cell lung carcinoma incident cases

    140 small-cell lung carcinomas

    PMID 32806637 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    coffee (27.4%), green tea (21.6%), potato (11.0%), vegetables (10.8%), and biscuits (10.6%)

    PMID 32825036 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    coffee (27.4%), green tea (21.6%), potato (11.0%), vegetables (10.8%), and biscuits (10.6%)

    PMID 32825036 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    coffee (27.4%), green tea (21.6%), potato (11.0%), vegetables (10.8%), and biscuits (10.6%)

    PMID 32825036 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    coffee (27.4%), green tea (21.6%), potato (11.0%), vegetables (10.8%), and biscuits (10.6%)

    PMID 32825036 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    coffee (27.4%), green tea (21.6%), potato (11.0%), vegetables (10.8%), and biscuits (10.6%)

    PMID 32825036 · one of two readings recorded this

  • incident liver cancer, multivariable Cox hazard ratio for highest vs lowest tertile of energy-adjusted dietary acrylamide intake (FFQ), model 1 and model 2 additionally adjusted for coffee

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    However, the statistically significant decrease disappeared after additional adjustment for coffee consumption (HR = 1.08; 95% CI = 0.87–1.34).

    PMID 32825036 · one of two readings recorded this

  • incident liver cancer (registry-ascertained) by tertile of energy-adjusted dietary acrylamide intake, multivariable Cox HR, model 1 and model 2 (additionally adjusted for coffee)

    decreases, p = 0.01

    Not recorded as a finding: this platform holds no node for the endpoint

    Subjects with a high acrylamide intake (T3) had a 21% lower liver cancer risk than those who had a low acrylamide intake (T1) (HR = 0.79; 95% CI = 0.65–0.95; P trend = 0.01) in model 1.

    PMID 32825036 · one of two readings recorded this

  • liver cancer incident cases

    744 cases of liver cancer were ascertained among the 85,305 eligible participants

    PMID 32825036 · one of two readings recorded this

  • liver cancer risk, model 1, p for trend across tertiles

    decreases, p = 0.01

    (HR = 0.79; 95% CI = 0.65–0.95; P trend = 0.01) in model 1

    PMID 32825036 · one of two readings recorded this

  • liver cancer risk, model 1

    decreases

    (HR = 0.79; 95% CI = 0.65–0.95; P trend = 0.01) in model 1

    PMID 32825036 · one of two readings recorded this

  • liver cancer risk, model 1

    decreases, p = 0.01

    an increased acrylamide intake reduced the risk of liver cancer among coffee drinkers in the multivariable model 1 (HR = 0.74; 95% CI = 0.58–0.94; P trend = 0.01)

    PMID 32825036 · one of two readings recorded this

  • liver cancer risk, model 2 (additionally adjusted for coffee consumption)

    no effect

    the statistically significant decrease disappeared after additional adjustment for coffee consumption (HR = 1.08; 95% CI = 0.87–1.34)

    PMID 32825036 · one of two readings recorded this

  • liver cancer risk, model 2 (additionally adjusted for coffee consumption)

    no effect

    the inverse association disappeared after additional adjustment in the multivariable model 2 (HR = 1.05; 95% CI = 0.80–1.38)

    PMID 32825036 · one of two readings recorded this

  • mean energy-adjusted acrylamide intake

    the mean intake (±SD) of acrylamide by our study population was 6.9 ± 3.8 µg per day

    PMID 32825036 · one of two readings recorded this

  • contribution to dietary acrylamide intake by quartile: biscuits/cookies

    increases

    biscuits or/and cookies: Q1: 6%, Q4: 13%

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake by quartile: coffee

    increases

    coffee: Q1: 14%, Q4: 36%

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake by quartile: vegetables

    decreases

    vegetables: Q1: 17%, Q4: 7%

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    vegetables (total 11%; 3% for sweet pepper, 3% for onion, 3% for bean sprouts, and 2% for others)

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    beverages (total 53%; 28% for coffee, 21% for green tea, 2% for beer, and 2% for others)

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    beverages (total 53%; 28% for coffee, 21% for green tea, 2% for beer, and 2% for others)

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    confections (total 16%; 11% for biscuits/cookies, 3% for chocolate, and 2% for others)

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    confections (total 16%; 11% for biscuits/cookies, 3% for chocolate, and 2% for others)

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    beverages (total 53%; 28% for coffee, 21% for green tea, 2% for beer, and 2% for others)

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    confections (total 16%; 11% for biscuits/cookies, 3% for chocolate, and 2% for others)

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    beverages (total 53%; 28% for coffee, 21% for green tea, 2% for beer, and 2% for others)

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    vegetables (total 11%; 3% for sweet pepper, 3% for onion, 3% for bean sprouts, and 2% for others)

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    vegetables (total 11%; 3% for sweet pepper, 3% for onion, 3% for bean sprouts, and 2% for others)

    PMID 33266487 · one of two readings recorded this

  • contribution to dietary acrylamide intake

    vegetables (total 11%; 3% for sweet pepper, 3% for onion, 3% for bean sprouts, and 2% for others)

    PMID 33266487 · one of two readings recorded this

  • mean acrylamide intake per body weight

    corresponding to 0.13 ± 0.16 μg/kg body weight/day

    PMID 33266487 · one of two readings recorded this

  • mean acrylamide intake

    The overall median acrylamide intake was 6.12 μg/d (IQR, 4.30–8.72), and the mean (SD) was 6.92 ± 3.81 μg/d

    PMID 33266487 · one of two readings recorded this

  • median acrylamide intake

    The overall median acrylamide intake was 6.12 μg/d (IQR, 4.30–8.72), and the mean (SD) was 6.92 ± 3.81 μg/d

    PMID 33266487 · one of two readings recorded this

  • pancreatic cancer incident cases

    During a mean follow-up of 15.2 years, 576 pancreatic cancer cases were identified

    PMID 33266487 · one of two readings recorded this

  • pancreatic cancer risk, p for trend across quartiles

    no effect, p = 0.07

    the HR of the highest quartile vs. the lowest was 0.83 (95% CI: 0.65–1.05) (p for trend = 0.07)

    PMID 33266487 · one of two readings recorded this

  • pancreatic cancer risk, p for trend across quartiles

    no effect, p = 0.2

    consumption of <150 g/week of alcohol (p for trend = 0.20)

    PMID 33266487 · one of two readings recorded this

  • pancreatic cancer risk, p for trend across quartiles

    no effect, p = 0.11

    BMI <25 kg/m2 (p for trend = 0.11)

    PMID 33266487 · one of two readings recorded this

  • pancreatic cancer risk, p for trend across quartiles

    no effect, p = 0.11

    consumption of <1 cup/week of coffee (p for trend = 0.11)

    PMID 33266487 · one of two readings recorded this

  • pancreatic cancer risk, p for trend across quartiles

    no effect, p = 0.25

    current or past smoking status (p for trend = 0.25)

    PMID 33266487 · one of two readings recorded this

  • pancreatic cancer risk, p for trend across quartiles

    no effect, p = 0.23

    consumption of <1 cup/week of green tea (p for trend = 0.23)

    PMID 33266487 · one of two readings recorded this

  • pancreatic cancer risk, p for trend across quartiles

    no effect, p = 0.23

    never smoking status (p for trend = 0.23)

    PMID 33266487 · one of two readings recorded this

  • pancreatic cancer risk

    no effect

    the HR of the highest quartile vs. the lowest was 0.83 (95% CI: 0.65–1.05) (p for trend = 0.07)

    PMID 33266487 · one of two readings recorded this

  • contribution to total acrylamide intake

    coffee (27.4%), green tea (21.6%), potatoes and starches (11.0%), vegetables (10.8%), and biscuits and cookies (10.6%) mainly contributed to the total acrylamide intake

    PMID 33670108 · one of two readings recorded this

  • contribution to total acrylamide intake

    coffee (27.4%), green tea (21.6%), potatoes and starches (11.0%), vegetables (10.8%), and biscuits and cookies (10.6%) mainly contributed to the total acrylamide intake

    PMID 33670108 · one of two readings recorded this

  • contribution to total acrylamide intake

    coffee (27.4%), green tea (21.6%), potatoes and starches (11.0%), vegetables (10.8%), and biscuits and cookies (10.6%) mainly contributed to the total acrylamide intake

    PMID 33670108 · one of two readings recorded this

  • contribution to total acrylamide intake

    coffee (27.4%), green tea (21.6%), potatoes and starches (11.0%), vegetables (10.8%), and biscuits and cookies (10.6%) mainly contributed to the total acrylamide intake

    PMID 33670108 · one of two readings recorded this

  • contribution to total acrylamide intake

    coffee (27.4%), green tea (21.6%), potatoes and starches (11.0%), vegetables (10.8%), and biscuits and cookies (10.6%) mainly contributed to the total acrylamide intake

    PMID 33670108 · one of two readings recorded this

  • incident malignant lymphoma, multiple myeloma and leukemia (ICD-O-3 morphology codes, registry and hospital ascertainment), multivariable Cox hazard ratio for dietary acrylamide intake tertiles

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    The results did not support that the daily acrylamide intake was associated with ML overall (HR for T2, 1.07; 95% CI: 0.82–1.40; HR for T3, 0.87; 95% CI 0.64–1.18).

    PMID 33670108 · one of two readings recorded this

  • incident malignant lymphoma, multiple myeloma and leukemia (registry-confirmed, ICD-O-3 morphology codes) by tertile of energy-adjusted dietary acrylamide intake, multivariable Cox HR

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    The results did not support that the daily acrylamide intake was associated with ML overall (HR for T2, 1.07; 95% CI: 0.82–1.40; HR for T3, 0.87; 95% CI 0.64–1.18).

    PMID 33670108 · one of two readings recorded this

  • leukemia incident cases

    326, 126, and 224 new cases of ML, MM, and leukemia had been identified, respectively

    PMID 33670108 · one of two readings recorded this

  • leukemia risk, interaction with smoking status

    p = 0.13

    representing p-value for interaction was 0.13

    PMID 33670108 · one of two readings recorded this

  • leukemia risk, p for trend across tertiles

    no effect, p = 0.94

    (HR for T2, 1.01; 95% CI: 0.73–1.40; HR for T3, 1.01; 95% CI 0.71–1.45; p for trend = 0.94)

    PMID 33670108 · one of two readings recorded this

  • leukemia risk, p for trend across tertiles

    no effect, p = 0.89

    (HR for T2, 1.04; 95% CI: 0.73–1.49; HR for T3, 1.03; 95% CI 0.70–1.52; p for trend = 0.89)

    PMID 33670108 · one of two readings recorded this

  • leukemia risk

    no effect

    (HR for T2, 1.01; 95% CI: 0.73–1.40; HR for T3, 1.01; 95% CI 0.71–1.45; p for trend = 0.94)

    PMID 33670108 · one of two readings recorded this

  • leukemia risk

    no effect

    (HR for T2, 1.01; 95% CI: 0.73–1.40; HR for T3, 1.01; 95% CI 0.71–1.45; p for trend = 0.94)

    PMID 33670108 · one of two readings recorded this

  • leukemia risk

    no effect

    the risks of leukemia for T2 (HR, 1.42; 95% CI, 0.78–2.59) and T3 (HR, 1.33; 95% CI, 0.69–2.59)

    PMID 33670108 · one of two readings recorded this

  • leukemia risk

    no effect

    For never smokers, the risks for T2 (HR, 0.82; 95%CI, 0.53–1.27) and T3 (HR, 0.86; 95%CI, 0.53–1.37)

    PMID 33670108 · one of two readings recorded this

  • leukemia risk

    no effect

    (HR for T2, 1.04; 95% CI: 0.73–1.49; HR for T3, 1.03; 95% CI 0.70–1.52; p for trend = 0.89)

    PMID 33670108 · one of two readings recorded this

  • leukemia risk

    no effect

    the risks of leukemia for T2 (HR, 1.42; 95% CI, 0.78–2.59) and T3 (HR, 1.33; 95% CI, 0.69–2.59)

    PMID 33670108 · one of two readings recorded this

  • leukemia risk

    no effect

    For never smokers, the risks for T2 (HR, 0.82; 95%CI, 0.53–1.27) and T3 (HR, 0.86; 95%CI, 0.53–1.37)

    PMID 33670108 · one of two readings recorded this

  • leukemia risk

    no effect

    (HR for T2, 1.04; 95% CI: 0.73–1.49; HR for T3, 1.03; 95% CI 0.70–1.52; p for trend = 0.89)

    PMID 33670108 · one of two readings recorded this

  • malignant lymphoma incident cases

    326, 126, and 224 new cases of ML, MM, and leukemia had been identified, respectively

    PMID 33670108 · one of two readings recorded this

  • malignant lymphoma risk, interaction with smoking status

    no effect, p = 0.38

    The HRs for acrylamide intake did not differ by smoking status (p for interaction = 0.38)

    PMID 33670108 · one of two readings recorded this

  • malignant lymphoma risk, p for trend

    no effect, p = 0.48

    The risk of ever smokers also did not increase with increasing acrylamide intake (p for trend = 0.48)

    PMID 33670108 · one of two readings recorded this

  • malignant lymphoma risk

    no effect

    The HR for 10 µg per day increment of acrylamide intake was 0.98 (95% CI, 0.94–1.01)

    PMID 33670108 · one of two readings recorded this

  • malignant lymphoma risk

    no effect

    (HR for T2, 1.07; 95% CI: 0.82–1.40; HR for T3, 0.87; 95% CI 0.64–1.18)

    PMID 33670108 · one of two readings recorded this

  • malignant lymphoma risk

    no effect

    (HR for T2, 1.07; 95% CI: 0.82–1.40; HR for T3, 0.87; 95% CI 0.64–1.18)

    PMID 33670108 · one of two readings recorded this

  • malignant lymphoma risk

    no effect

    the HR of the T3 group was lower than that of the T1 group; nevertheless, the difference was not significant (HR, 0.72; 95%CI, 0.48–1.10)

    PMID 33670108 · one of two readings recorded this

  • mean dietary acrylamide intake estimated from dietary records

    while the mean intake estimated from DRs were 6.78 μg per day (SD = 3.89) and 7.25 μg per day (SD = 3.33), respectively

    PMID 33670108 · one of two readings recorded this

  • mean dietary acrylamide intake estimated from dietary records

    while the mean intake estimated from DRs were 6.78 μg per day (SD = 3.89) and 7.25 μg per day (SD = 3.33), respectively

    PMID 33670108 · one of two readings recorded this

  • mean dietary acrylamide intake estimated from FFQ

    the mean dietary acrylamide intake estimated from the FFQ for Cohorts I and II were 7.03 μg per day (standard deviation [SD] = 4.30) and 7.14 μg per day (SD = 3.38)

    PMID 33670108 · one of two readings recorded this

  • mean dietary acrylamide intake estimated from FFQ

    the mean dietary acrylamide intake estimated from the FFQ for Cohorts I and II were 7.03 μg per day (standard deviation [SD] = 4.30) and 7.14 μg per day (SD = 3.38)

    PMID 33670108 · one of two readings recorded this

  • median daily acrylamide intake

    The median (interquartile range, IQR) daily acrylamide intake (µg/day) were 3.58 (1.45) for T1, 6.09 (1.34) for T2, and 10.11 (3.67) for T3

    PMID 33670108 · one of two readings recorded this

  • median daily acrylamide intake

    The median (interquartile range, IQR) daily acrylamide intake (µg/day) were 3.58 (1.45) for T1, 6.09 (1.34) for T2, and 10.11 (3.67) for T3

    PMID 33670108 · one of two readings recorded this

  • median daily acrylamide intake

    The median (interquartile range, IQR) daily acrylamide intake (µg/day) were 3.58 (1.45) for T1, 6.09 (1.34) for T2, and 10.11 (3.67) for T3

    PMID 33670108 · one of two readings recorded this

  • multiple myeloma incident cases

    326, 126, and 224 new cases of ML, MM, and leukemia had been identified, respectively

    PMID 33670108 · one of two readings recorded this

  • multiple myeloma risk, interaction with smoking status

    no effect, p = 0.24

    The interaction term between acrylamide intake and smoking status did not show significant difference (p for interaction = 0.24)

    PMID 33670108 · one of two readings recorded this

  • multiple myeloma risk

    no effect

    Although the HR of the T3 group was 0.64 (95% CI, 0.38–1.05) in multivariable-adjusted model

    PMID 33670108 · one of two readings recorded this

  • bladder cancer incident cases

    a total of 208 cases of renal cell cancer and 392 incident cases of bladder cancer were ascertained during 1,346,982 person-years of follow-up

    PMID 33673718 · one of two readings recorded this

  • bladder cancer risk, p for trend across tertiles

    no effect, p = 0.491

    the HR (95% CI) in the multivariate-adjusted model was 0.89 (0.62–1.32) in the middle group (T2) and 0.87 (0.59–1.29) in the highest (T3) with respect to bladder cancer (p for trend = 0.491)

    PMID 33673718 · one of two readings recorded this

  • bladder cancer risk

    no effect

    the HR (95% CI) in the multivariate-adjusted model was 0.89 (0.62–1.32) in the middle group (T2) and 0.87 (0.59–1.29) in the highest (T3) with respect to bladder cancer (p for trend = 0.491)

    PMID 33673718 · one of two readings recorded this

  • bladder cancer risk

    no effect

    the HR (95% CI) in the multivariate-adjusted model was 0.89 (0.62–1.32) in the middle group (T2) and 0.87 (0.59–1.29) in the highest (T3) with respect to bladder cancer (p for trend = 0.491)

    PMID 33673718 · one of two readings recorded this

  • incident prostate cancer and incident urinary bladder cancer (registry-ascertained, ICD-O-3) by tertile of energy-adjusted dietary acrylamide intake, multivariate Cox HR; incident renal cell cancer also measured (no outcome node)

    prostate cancer HR 0.96 (0.75–1.22) for highest versus lowest tertile, multivariate-adjusted, p = 0.726

    Not recorded as a finding: the direction is carried only as a signed number

    Compared to the lowest intake group (T1), the HR (95% CI) in the multivariate-adjusted model was 0.92 (0.73–1.17) in the middle group (T2) and 0.96 (0.75–1.22) in the highest (T3) with respect to prostate cancer (p for trend = 0.726) (Table 3).

    PMID 33673718 · one of two readings recorded this

  • incident prostate cancer (ICD-O-3 C61) and incident bladder cancer (C67) by cancer registry and hospital notification, multivariate Cox hazard ratio for highest vs lowest tertile of energy-adjusted dietary acrylamide intake (FFQ); renal cell cancer (C64) also measured

    p = 0.726

    Not recorded as a finding: the direction is carried only as a signed number

    Compared to the lowest intake group (T1), the HR (95% CI) in the multivariate-adjusted model was 0.92 (0.73–1.17) in the middle group (T2) and 0.96 (0.75–1.22) in the highest (T3) with respect to prostate cancer (p for trend = 0.726) (Table 3).

    PMID 33673718 · one of two readings recorded this

  • mean dietary acrylamide intake

    The mean (± SD) dietary acrylamide intakes in the study population were 3.6 (1.5) μg/day, 6.4 (2.0) μg/day, and 11.2 (4.5) μg/day in the lowest, middle, and highest tertiles of dietary acrylamide intake, respectively

    PMID 33673718 · one of two readings recorded this

  • mean dietary acrylamide intake

    The mean (± SD) dietary acrylamide intakes in the study population were 3.6 (1.5) μg/day, 6.4 (2.0) μg/day, and 11.2 (4.5) μg/day in the lowest, middle, and highest tertiles of dietary acrylamide intake, respectively

    PMID 33673718 · one of two readings recorded this

  • mean dietary acrylamide intake

    The mean (± SD) dietary acrylamide intakes in the study population were 3.6 (1.5) μg/day, 6.4 (2.0) μg/day, and 11.2 (4.5) μg/day in the lowest, middle, and highest tertiles of dietary acrylamide intake, respectively

    PMID 33673718 · one of two readings recorded this

  • prostate cancer incident cases

    With respect to prostate cancer, 1195 cases were ascertained during 605,324 person-years of follow-up

    PMID 33673718 · one of two readings recorded this

  • prostate cancer risk, p for trend across tertiles

    no effect, p = 0.726

    the HR (95% CI) in the multivariate-adjusted model was 0.92 (0.73–1.17) in the middle group (T2) and 0.96 (0.75–1.22) in the highest (T3) with respect to prostate cancer (p for trend = 0.726)

    PMID 33673718 · one of two readings recorded this

  • prostate cancer risk

    no effect

    the HR (95% CI) in the multivariate-adjusted model was 0.92 (0.73–1.17) in the middle group (T2) and 0.96 (0.75–1.22) in the highest (T3) with respect to prostate cancer (p for trend = 0.726)

    PMID 33673718 · one of two readings recorded this

  • prostate cancer risk

    no effect

    the HR (95% CI) in the multivariate-adjusted model was 0.92 (0.73–1.17) in the middle group (T2) and 0.96 (0.75–1.22) in the highest (T3) with respect to prostate cancer (p for trend = 0.726)

    PMID 33673718 · one of two readings recorded this

  • renal cell cancer incident cases

    a total of 208 cases of renal cell cancer and 392 incident cases of bladder cancer were ascertained during 1,346,982 person-years of follow-up

    PMID 33673718 · one of two readings recorded this

  • renal cell cancer risk, p for trend across tertiles

    no effect, p = 0.294

    the HR (95% CI) in the multivariate-adjusted model was 0.83 (0.45–1.53) in the middle group (T2) and 0.71 (0.38–1.34) in the highest (T3) (p for trend = 0.294)

    PMID 33673718 · one of two readings recorded this

  • renal cell cancer risk

    no effect

    the HR (95% CI) in the multivariate-adjusted model was 0.83 (0.45–1.53) in the middle group (T2) and 0.71 (0.38–1.34) in the highest (T3) (p for trend = 0.294)

    PMID 33673718 · one of two readings recorded this

The whole record — 445 rows